Condition

HIV Pre-exposure Prophylaxis

ClinicalTrials.gov condition label

Clinical trials14

Recruiting4

Common interventions19

Lead sponsors shown12

Clinical trials

14 shown

PEP/PrEP Via Pharmacist-Prescribing Implementation (PEPPI)NCT07683117 · 2026-08-01

HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department StudyNCT07462611 · 2026-04-08

Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEPNCT07218211 · 2026-01-13

HIV Testing Counselor-led Care to Catalyze Integration of PrEP Delivery in Family Planning ClinicsNCT07089966 · 2025-12-01

Optimizing PrEP Uptake for African American Women in the South by Empowering Women to Make Informed HIV Prevention and Sexual Health ChoicesNCT07173816 · 2026-10-01

NOT_YET_RECRUITING

Trauma-informed, Resilience-based Telehealth Intervention for Improving HIV Prevention and HCV Care for Persons Who Inject Drugs in the Deep South (Pilot Testing: Aim3)NCT06799702 · 2026-08-01

NOT_YET_RECRUITING

Long-Acting Injectable HIV PrEP PROsNCT07379658 · 2026-01-15

NOT_YET_RECRUITING

Client-Centered Care Coordination for Black Men Who Have Sex With MenNCT06056544 · 2025-12-21

ENROLLING_BY_INVITATION

Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)NCT07047716 · 2025-07-22

ACTIVE_NOT_RECRUITING

A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)NCT06580587 · 2025-04-15

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With MenNCT06205368 · 2024-03-27

ACTIVE_NOT_RECRUITING

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)NCT06045507 · 2023-11-08

MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender WomenNCT07146139 · 2023-03-18

Adapting an Adolescent Friendly PrEP Program for Uasin Gishu County-KenyaNCT05545449 · 2022-09-14

Common interventions

MK-8527DRUG2 Client Centered Care CoordinationBEHAVIORAL1 Combine mobile appBEHAVIORAL1 EMPOWERBEHAVIORAL1 HIV/STI testingBEHAVIORAL1 HTS counselor-led PrEP care modelOTHER1 Interview and survey to evaluate patient reported outcomes between the two medications.OTHER1 Lenacapavir InjectionDRUG1 Lenacapavir long-actingDRUG1 Lenacapavir TabletDRUG1 Motivational interviewBEHAVIORAL1 MyPrEP Plus PackageDEVICE1 PEPPI PharmaciesOTHER1 Placebo to MK-8527DRUG1 Pre-Exposure Prophylaxis (PrEP) PersistenceBEHAVIORAL1 PrEP Peer Mentor ProgramBEHAVIORAL1 PrEP Uptake with Rapid StartBEHAVIORAL1 Standard of Care (SOC)BEHAVIORAL1 Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)BEHAVIORAL1

Leading sponsors

Merck Sharp & Dohme LLC2 University of Georgia2 Anupama Raghuram MD1 Duke University1 Emory University1 EMPOWERX INC1 Gilead Sciences1 Indiana University1 Public Health Foundation Enterprises, Inc.1 University of Maryland, Baltimore1 University of Texas Southwestern Medical Center1 University of Washington1

Trial status mix

RECRUITING4

COMPLETED3

NOT_YET_RECRUITING3

ACTIVE_NOT_RECRUITING2

ENROLLING_BY_INVITATION1

TERMINATED1

Phase mix

NA8

PHASE11

PHASE21

PHASE31

PHASE41

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.